Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Information source: Geha Mental Health Center
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia; Treatment Resistant Disorders
Intervention: Clozapine (Drug); Amisulpride (Drug); Clozapine+Amisulpride (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Geha Mental Health Center Overall contact: Amir Krivoy, M.D., Phone: 972-3-9258230, Email: akrivoy@clalit.org.il
Summary
Background: schizophrenia is a debilitating mental disorder affecting about 1% of the
general population. About 30% of patients will not react to current drug treatment and
defined as treatment-resistant schizophrenia patients (TRSP). The best studied therapeutic
option for this population is clozapine therapy. Clozapine was shown to be effective than
any other antipsychotic drug in TRSP. Moreover, augmentation of clozapine was not
demonstrated to be more effective than clozapine monotherapy. Albeit Clozapine superiority
in TRSP, its use may be involved with many adverse effects, some of them are
life-threatening, and need for routine blood tests. Amisulpride is an atypical antipsychotic
drug with a different mechanism of action than clozapine, with less adverse effects. No
study compared directly amisulpride and clozapine in TRSP.
Study objective: to compare, for the first time, the broad clinical effectiveness of
clozapine and amisulpride and their combination in TRSP.
Study Design: a clinical, prospective, naturalistic, randomized, comparative study
simulating a real-world approach of clinical decision making.
Methods: a total of 140 TRSP will be recruited from a large regional mental health center.
Participants will be randomized into two treatment groups (70 in each group): clozapine
monotherapy and amisulpride monotherapy. Assessment will be done following 10 and 20 weeks
of treatment. In case of treatment failure (insufficient clinical response or severe
adverse effect) participants will be offered either to switch to clozapine treatment (for
failed amisulpride treatment) or to augment clozapine with amisulpride (for failed clozapine
monotherapy patients). Thereafter, participants will be followed-up for a year. Assessment
will be made using clinician rated scales and self-completed questionnaires, rating the
broad phenomenology of schizophrenia (psychosis, mood, anxiety, obsessive-compulsive,
cognitive and quality of life) and drug-related adverse effects (objective and subjective).
Analysis: comparison of the effectiveness of the three treatment groups: amisulpride,
clozapine and their combination, in the various dimensions of TRSP.
Clinical Details
Official title: Clozapine Versus Amisulpride Versus Their Combination in the Treatment of Drug-resistant Schizophrenia Patients
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Change from baseline in Positive and Negative Syndrome Scale (PANSS)
Secondary outcome: Change from baseline in Clinical Global Impression - Severity (CGI-S)Change from baseline in Beck Depression Inventory (BDI) Change from baseline in Beck Anxiety Inventory (BAI) Change from baseline in Schizophrenia Quality of Life Scale (SQLS) Change from baseline in Simpson-Angus Scale (SAS) Change from baseline in Clozapine Adverse Effects Inventory (CAEI)
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Confirmed diagnosis of schizophrenia according to DSM-IV-TR criteria
2. Treatment-resistant schizophrenia, defined as: documented treatment failure
(insufficient clinical response or severe adverse effects) of two antipsychotics (one
of them should be atypical) for an adequate duration of 6 weeks and in a sufficient
dose of at least 600 mg/day of chlorpromazine equivalent
3. Age 18-65 years
4. Basal PANSS > 75
5. CGI-S >3
6. Persistent positive psychotic symptoms, with rating scores of moderate or worse on at
least two of four positive symptom items (delusions, conceptual disorganization,
hallucinatory behavior, and suspiciousness/persecution) on Positive and Negative
Syndrome Scale (PANSS).
7. Competent and willing to provide written, informed consent
Exclusion Criteria:
1. Patients with concomitant treatment with lithium, anticonvulsants, antidepressants
2. Patients with underlying severe medical illness, such as cardiovascular disease,
cerebrovascular disease, bone marrow suppression or epilepsy
3. A previous trial of clozapine or amisulpride
4. Any known contraindication for treatment with clozapine or amisulpride
5. Any woman who is pregnant or planning a pregnancy, and any woman of child bearing
potential unless using adequate contraception
Locations and Contacts
Amir Krivoy, M.D., Phone: 972-3-9258230, Email: akrivoy@clalit.org.il
Geha Mental Health Center, Petach-Tikva 49000, Israel; Recruiting
Additional Information
Starting date: October 2011
Last updated: December 4, 2012
|